MDxHealth SA (NASDAQ:MDXH) Given Average Recommendation of “Moderate Buy” by Brokerages

MDxHealth SA (NASDAQ:MDXH) has been given an average rating of “Moderate Buy” by the five analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $7.75.

Several research analysts recently weighed in on the company. TD Cowen lifted their price target on MDxHealth from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MDxHealth in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of MDxHealth to a “hold” rating in a research note on Saturday, August 30th. BTIG Research raised their price target on shares of MDxHealth from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Lake Street Capital lifted their price objective on shares of MDxHealth from $7.00 to $9.00 and gave the company a “buy” rating in a report on Thursday.

Hedge Funds Weigh In On MDxHealth

A number of large investors have recently bought and sold shares of MDXH. AWM Investment Company Inc. boosted its position in MDxHealth by 10.6% during the first quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company’s stock worth $7,414,000 after acquiring an additional 499,992 shares during the last quarter. Perkins Capital Management Inc. lifted its stake in MDxHealth by 20.1% in the 1st quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company’s stock worth $1,678,000 after purchasing an additional 198,000 shares in the last quarter. Delta Investment Management LLC boosted its holdings in shares of MDxHealth by 459.1% during the 1st quarter. Delta Investment Management LLC now owns 190,100 shares of the company’s stock worth $270,000 after purchasing an additional 156,100 shares during the last quarter. FreeGulliver LLC purchased a new stake in shares of MDxHealth in the second quarter valued at approximately $273,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of MDxHealth in the third quarter valued at approximately $461,000.

MDxHealth Stock Performance

Shares of MDxHealth stock traded down $0.13 during trading on Thursday, hitting $4.00. 216,005 shares of the company’s stock were exchanged, compared to its average volume of 120,154. MDxHealth has a 52-week low of $1.35 and a 52-week high of $5.33. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.22 and a current ratio of 1.31. The stock has a market capitalization of $188.92 million, a price-to-earnings ratio of -4.54 and a beta of 1.68. The business has a 50-day simple moving average of $4.31 and a 200-day simple moving average of $3.04.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $27.43 million for the quarter, compared to analyst estimates of $24.11 million. MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%. MDxHealth has set its FY 2025 guidance at EPS. On average, research analysts forecast that MDxHealth will post -1.15 EPS for the current year.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.